Pharmacosmos A/S clinical trials

Part of Pharmacosmos Holding A/S, which holds 100% as of 2025-04-30. Source

The registry lists 54 studies whose lead sponsor is Pharmacosmos A/S or one of 3 companies grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 5, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 54. Browse all 54 →

• Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart FailureRecruitingNCT06929806Phase 3
• Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung CancerRecruitingNCT07473128Phase 3
• Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency AnemiaRecruitingNCT05179226Phase 3
• A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic SyndromesRecruitingNCT05693909Phase 2
• A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous TransplantationNot yet recruitingNCT05545202Phase 4
• Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving TopotecanActive, not recruitingNCT05874401Phase 4
• G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast CancerCompletedNCT03455270Phase 1

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCCompletedNCT03041311Phase 2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan ChemotherapyCompletedNCT02514447Phase 1/2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then AvelumabTerminatedNCT04887831Phase 2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerTerminatedNCT05113966Phase 2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):TerminatedNCT04607668Phase 3

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT04799249Phase 3

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast CancerCompletedNCT05112536Phase 2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung CancerCompletedNCT03455829Phase 1/2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Docetaxel for Metastatic Non-Small Cell Lung Cancer (NSCLC) (PRESERVE 4)TerminatedNCT04863248Phase 2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerStatus unknownNCT02983071Phase 1/2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)TerminatedNCT02978716Phase 2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung CancerApproved for marketingNCT04504513

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel DiseaseCompletedNCT03466983Phase 4
• Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.CompletedNCT03188445Phase 4
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney DiseaseCompletedNCT02940860Phase 3
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)CompletedNCT02940886Phase 3
• SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare AnemiasWithdrawnNCT03801889Phase 2

  Sponsor listed in the registry: Abfero Pharmaceuticals, Inc · First submitted before Abfero Pharmaceuticals, Inc became part of Pharmacosmos A/S

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)CompletedNCT02499770Phase 1/2

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)CompletedNCT02962648Phase 3
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency AnaemiaCompletedNCT03237065Phase 3
• Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency AnaemiaCompletedNCT03238911Phase 3
• Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)CompletedNCT02546154

  Sponsor listed in the registry: Pharmacosmos UK Ltd

• Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1CompletedNCT02243150Phase 1

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron SucroseCompletedNCT02130063Phase 3
• A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood DonorsCompletedNCT01895231Phase 3
• Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)CompletedNCT03013439Phase 1
• First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy VolunteersCompletedNCT02821624Phase 1

  Sponsor listed in the registry: G1 Therapeutics, Inc. · First submitted before G1 Therapeutics, Inc. became part of Pharmacosmos A/S

• A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron DeficiencyCompletedNCT02301026
• A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against PlaceboWithdrawnNCT02172001Phase 3
• Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)CompletedNCT01900197
• A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)CompletedNCT01145638Phase 3
• Iron Isomaltoside 1000 (Monofer®) in Non-Dialysis Dependent Chronic Kidney Disease and With Renal-Related AnaemiaCompletedNCT01102413Phase 3
• A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5DCompletedNCT01222884Phase 3
• Treatment of Women After Severe Postpartum HaemorrhageCompletedNCT01895205Phase 3
• IV Iron Treatment of Restless Legs SyndromeWithdrawnNCT02484768Phase 2
• Treatment of Women After Postpartum HaemorrhageCompletedNCT01895218Phase 3
• Iron Isomaltoside 1000 (Monofer®) Administered by a High Dosing Regimen in Subjects With Inflammatory Bowel DiseaseCompletedNCT01599702Phase 3
• A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination ThereofCompletedNCT01563367Phase 3
• Safety and Efficacy Extension Study of Iron Isomaltoside 1000 (Monofer®) in Subjects With Inflammatory Bowel DiseaseCompletedNCT01410435Phase 3
• Open-label PK Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Injection or 1000 mg IV Infusion to Patients With Inflammatory Bowel DiseaseCompletedNCT01213680Phase 1
• Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous to Patients With CKDCompletedNCT01213992Phase 1
• Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)CompletedNCT01213979Phase 1
• Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced AnaemiaCompletedNCT01280240Phase 1